Drugs / TAF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02979613 | Dec 2016 → Sep 2018 | chronic hepatitis B virus infection | Gilead Sciences | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02979613 ↗ |
| Route | Oral | “25 mg tablet administered orally once daily” NCT02979613 ↗ |